D. Mulherin

发表

Survey of artificial tear and saliva usage among patients with Sjögren's syndrome

S. Bowman, B. Speculand, J. Ainsworth, 2001, Annals of the rheumatic diseases.

Identification of risk factors for future fracture in patients following distal forearm fracture

S. Williams, J. Edwards, T. Sheeran, 2003, Osteoporosis International.

Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.

R. Cooper, L. Kay, J. Ledingham, 2007, Rheumatology.

Anti-tumour necrosis factor treatment in a patient with anorexia nervosa and juvenile idiopathic arthritis

T. Sheeran, D. Mulherin, J. Barber, 2003, Annals of the rheumatic diseases.

Glutathione reductase activity, riboflavin status, and disease activity in rheumatoid arthritis.

R. D. Situnayake, D. Thurnham, D. Mulherin, 1996, Annals of the rheumatic diseases.

Multiple haematological malignancies in a patient with rheumatoid arthritis without exposure to disease modifying therapy

N. Hardwick, D. Mulherin, H. Piper, 2006, Annals of the rheumatic diseases.

Do gold rings protect against articular erosion in rheumatoid arthritis?

R. D. Situnayake, D. Mulherin, D. Mulherin, 1997, Annals of the rheumatic diseases.

Is parenteral methotrexate worth trying?

D. Mulherin, A. Osman, 2001, Annals of the rheumatic diseases.

Arthritic reactions following hepatitis B vaccination: an analysis of the vaccine adverse events reporting system (VAERS) data from 1990 through 1997.

D. Mulherin, J. A. Smith, T. Price, 2000 .

Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis

W. Dixon, A. Barton, I. Bruce, 2015, Arthritis & rheumatology.

Granulomatosis with polyangiitis and COVID-19 pneumonia

K. Iyengar, P. Ish, D. Mulherin, 2022, Indian Journal of Rheumatology.

Is pamidronate effective for acute rheumatic pain?

T. Sheeran, D. Mulherin, A. El-Shafei, 2002, Annals of the rheumatic diseases.

Sjögren's Systemic Clinical Activity Index (SCAI)--a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome.

D A Isenberg, D. Isenberg, A. Jones, 2007, Rheumatology.

The Sjögren's Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome.

R. Barry, D. Isenberg, A. Jones, 2008, Rheumatology.

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

S. Tuck, B. Harrison, B. Griffiths, 2022, Rheumatology.

Scoliosis and Trendelenburg Sign in a Painting by P P Rubens Author's Response Comparison of Womac with Sf-36 for Oa of the Knee or Hip Authors' Response Antibodies to Β 2 Glycoprotein I and Cardiolipin in Ssc

J. Dequeker, F. Angst, A. Aeschlimann, 2022 .

Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

W. Dixon, I. Bruce, Paul Wordsworth, 2013, The Pharmacogenomics Journal.